2023
CTNI-41. PHASE II AND PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS
Schiff D, Bindra R, Li J, Ye X, Ellingson B, Walbert T, Campian J, Nabors B, Lieberman F, Ozer B, Desai A, Omuro A, Wen P, Desideri S, Danda N, Grossman S. CTNI-41. PHASE II AND PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS. Neuro-Oncology 2023, 25: v84-v84. PMCID: PMC10639307, DOI: 10.1093/neuonc/noad179.0323.Peer-Reviewed Original ResearchObjective response rateArm AMetronomic temozolomideArm BGrade 3Non-enhancing tumorMeaningful objective response rateTumor/plasma ratioCumulative hematologic toxicityGrade 3 anemiaGrade 3 thrombocytopeniaGrade 4 neutropeniaPhase II componentArm clinical trialPhase IIKPS 90Median PFSHematologic toxicityPrimary endpointAlkylator therapyProgressive diseaseARM patientsMedian ageBRCAness phenotypeClinical trials
2017
NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).
Galanis E, Anderson S, Butowski N, Hormigo A, Schiff D, Tran D, Omuro A, Jaeckle K, Kumar S, Kaufmann T, Buckner J, Twohy E, Giannini C, Wen P. NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance). Journal Of Clinical Oncology 2017, 35: 2023-2023. DOI: 10.1200/jco.2017.35.15_suppl.2023.Peer-Reviewed Original ResearchProgression-free survivalII trialMedian progression-free survivalRandomized phase II trialPhase II trialGlioma stem cellsOverall survivalOverall incidenceRecurrent glioblastomaMultiple time pointsVEGF inhibitionGrade 3GBM patientsPositive subsetSingle agentI cohortResponse rateHumanized antibodyFlow cytometryEndothelial cellsTime pointsTGFβ receptorsGlioblastomaBevacizumabCD105
2015
A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning
Scordo M, Bhatt V, Hsu M, Omuro A, Matasar M, DeAngelis L, Dahi P, Moskowitz C, Giralt S, Sauter C. A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning. Blood 2015, 126: 4354. DOI: 10.1182/blood.v126.23.4354.4354.Peer-Reviewed Original ResearchNon-hematologic toxicitiesProgression-free survivalKaplan-Meier curvesSignificant grade 3HDT-ASCTMore grade 3Whole brain radiotherapyKarnofsky performance statusOverall survivalCNS lymphomaGrade 3Prior regimensHematopoietic cell transplant comorbidity indexAutologous stem cell transplantationHigh-dose therapyTransplant-related mortalityKaplan-Meier methodProspective clinical trialsRetrospective chart reviewStem cell transplantationGroups of ptsInitiation of conditioningYears of ageBU pharmacokineticsCTCAE 4.0
2014
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology 2014, 17: 116-121. PMID: 25100872, PMCID: PMC4483051, DOI: 10.1093/neuonc/nou148.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor receptorPhase II trialWorld Health OrganizationGrowth factor receptorII trialPrimary endpointOverall survivalExploratory cohortIntratumoral hemorrhageGrade 3Small molecule tyrosine kinase inhibitorsSingle-arm phase II trialMalignant meningioma patientsRadiographic response rateMedian overall survivalEffective medical therapyProgression-free survivalFactor receptorEndothelial growth factor receptorPlatelet-derived growth factor receptorTyrosine kinase inhibitorsExpression of VEGFR2MR perfusion imagingHigh-grade meningiomasMedian PFS
2007
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Journal Of Neuro-Oncology 2007, 85: 207-211. PMID: 17896079, DOI: 10.1007/s11060-007-9397-0.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaIntra-thecal chemotherapyFavorable toxicity profileComplete responseToxicity profilePrimary central nervous system lymphomaMedian event-free survivalCentral nervous system lymphomaMedian overall survivalEvent-free survivalNervous system lymphomaNew alternative treatmentLow response rateInduction chemotherapyInnovative regimenCNS lymphomaElderly patientsIntestinal obstructionOverall survivalPCNSL patientsYounger patientsSystem lymphomaConsecutive seriesEfficacy resultsGrade 3
2006
Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial
Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE. Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial. Journal Of Neuro-Oncology 2006, 78: 277-280. PMID: 16614943, DOI: 10.1007/s11060-005-9095-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, AlkylatingAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungDacarbazineDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansLung NeoplasmsLymphopeniaMaleMaximum Tolerated DoseMiddle AgedNeutropeniaTemozolomideThrombocytopeniaTreatment OutcomeVinblastineVinorelbineConceptsCourses of temozolomideRecurrent brain metastasesBrain metastasesDose of vinorelbineProgressive brain metastasesPhase II trialPhase I trialEfficacy of temozolomideVinorelbine doseII trialStarting doseMedian survivalRadiographic responseI trialMedian ageModest efficacyNew regimenPatient 2Lung cancerPrimary tumorGrade 3PatientsVinorelbineTemozolomideDose